| Chelsea Kolshak, | |
|
1000 Blythe Blvd, Charlotte, NC 28203-5812 | |
| (704) 355-3658 | |
| Not Available |
| Full Name | Chelsea Kolshak |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Location | 1000 Blythe Blvd, Charlotte, North Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003132242 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 164526 (North Carolina) | Primary |
| Entity Name | Emergency Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285686675 PECOS PAC ID: 7911811435 Enrollment ID: O20040407000673 |
News Archive
ZIOPHARM Oncology, Inc. announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for Application Serial No. 11/257,766 entitled "Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents" with claims directed to compounds, pharmaceutical compositions, and lyophilisates. These claims cover the Company's proprietary palifosfamide composition (ZIO-201 or ZymafosTM). The Company has recently reported positive randomized Phase II sarcoma interim data for intravenous palifosfamide at the Annual Meeting of the Connective Tissue Oncology Society (CTOS) on November 6, 2009 and expects, following U.S. Food and Drug Administration (FDA) review, to initiate a registration trial the first half of 2010.
Celldex Therapeutics, Inc. today announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock, offered at a price to the public of $3.85 per share for an aggregate offering of $40,425,000 of common stock.
The U.S. Food and Drug Administration (FDA) has approved Zolinza (vorinostat) capsules for the treatment of cutaneous T-cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines.
Melanoma, a relatively rare but deadly skin cancer, has been shown to switch differentiation states - that is, to regress to an earlier stage of development - which can lead it to become resistant to treatment.
According to the latest research human breast milk holds the potential to assess a woman's risk of developing breast cancer.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Chelsea Kolshak, 1000 Blythe Blvd, Charlotte, NC 28203-5812 Ph: (704) 355-3658 | Chelsea Kolshak, 1000 Blythe Blvd, Charlotte, NC 28203-5812 Ph: (704) 355-3658 |
News Archive
ZIOPHARM Oncology, Inc. announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for Application Serial No. 11/257,766 entitled "Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents" with claims directed to compounds, pharmaceutical compositions, and lyophilisates. These claims cover the Company's proprietary palifosfamide composition (ZIO-201 or ZymafosTM). The Company has recently reported positive randomized Phase II sarcoma interim data for intravenous palifosfamide at the Annual Meeting of the Connective Tissue Oncology Society (CTOS) on November 6, 2009 and expects, following U.S. Food and Drug Administration (FDA) review, to initiate a registration trial the first half of 2010.
Celldex Therapeutics, Inc. today announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock, offered at a price to the public of $3.85 per share for an aggregate offering of $40,425,000 of common stock.
The U.S. Food and Drug Administration (FDA) has approved Zolinza (vorinostat) capsules for the treatment of cutaneous T-cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines.
Melanoma, a relatively rare but deadly skin cancer, has been shown to switch differentiation states - that is, to regress to an earlier stage of development - which can lead it to become resistant to treatment.
According to the latest research human breast milk holds the potential to assess a woman's risk of developing breast cancer.
› Verified 1 days ago
Jacob Leedekerken, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Blythe Blvd, Charlotte, NC 28203 Phone: 704-355-3181 | |
Neha Ray, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Blythe Blvd, Charlotte, NC 28203 Phone: 704-355-3181 Fax: 704-355-7047 | |
John B Clark Jr., M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1900 Randolph Rd, Ste 900, Charlotte, NC 28207 Phone: 704-377-2424 Fax: 704-377-2687 | |
Nilesh K. Patel, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Blythe Blvd, Charlotte, NC 28203 Phone: 704-355-2171 | |
Michael Stephen Merrill, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 501 S Sharon Amity Rd Ste 300, Charlotte, NC 28211 Phone: 704-377-2424 Fax: 704-377-2687 | |
Brian Zachary Hedges, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1000 Blythe Blvd., Cmc/department Of Emergency Medicine, Charlotte, NC 28203 Phone: 704-355-3181 Fax: 704-355-7047 |